TrialCurveAglatimagene besadenovec + radiotherapy in prostate cancer: reconstructed Kaplan–Meier curves
Aglatimagene besadenovec (CAN-2409) with radiotherapy for patients with localised prostate cancer: a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | Lancet Oncol. Author manuscript; Available in PMC 2026 Aug 5. |
|---|---|
| DOI | 10.1016/S1470-2045(26)00071-9 |
| Registry | NCT01436968 |
| Phase | Phase 3 |
| Conditions | Prostate Cancer |
| Interventions | Aglatimagene besadenovec + valacyclovir, Placebo + valacyclovir |
| Sponsor | Candel Therapeutics, Inc. |
| Enrolment | 711 |
| Source licence | Figure published under CC BY 4.0 |
Disease-free survival — ITT population
From figure panel A · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Median: Aglatimagene plus valacyclovir not reached; Placebo plus valacyclovir 97.6 months. Survival at 18 months: Aglatimagene plus valacyclovir 98%; Placebo plus valacyclovir 97%. Hazard ratio Aglatimagene plus valacyclovir vs Placebo plus valacyclovir 0.70 (95% CI 0.52–0.93).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Aglatimagene plus valacyclovir | 496 | 113 | not reached |
| Placebo plus valacyclovir | 249 | 75 | 97.6 |
- Aglatimagene plus valacyclovir vs Placebo plus valacyclovir: reconstructed HR 0.70 (95% CI 0.52–0.93)
Landmark survival (reconstructed)
| Time | Aglatimagene plus valacyclovir | Placebo plus valacyclovir |
|---|---|---|
| 6 mo | 99.8% | 100.0% |
| 12 mo | 99.1% | 99.1% |
| 18 mo | 97.5% | 97.3% |
| 24 mo | 95.7% | 96.3% |
| 36 mo | 79.9% | 71.1% |
| 48 mo | 75.9% | 68.6% |
| 60 mo | 73.5% | 64.7% |
Checks against the published figure
- Aglatimagene plus valacyclovir events: printed 113, reconstructed 113 pass
- Aglatimagene plus valacyclovir n: printed 496, reconstructed 496 pass
- Placebo plus valacyclovir events: printed 76, reconstructed 75 pass
- Placebo plus valacyclovir n: printed 249, reconstructed 249 pass
- hazard ratio: printed 0.7, reconstructed 0.697 pass
Prostate cancer-specific disease-free survival — ITT population
From figure panel A · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Median: Aglatimagene plus valacyclovir not reached; Placebo plus valacyclovir 142.9 months. Survival at 18 months: Aglatimagene plus valacyclovir 100%; Placebo plus valacyclovir 99%. Hazard ratio Aglatimagene plus valacyclovir vs Placebo plus valacyclovir 0.62 (95% CI 0.44–0.86).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Aglatimagene plus valacyclovir | 496 | 82 | not reached |
| Placebo plus valacyclovir | 249 | 62 | 142.9 |
- Aglatimagene plus valacyclovir vs Placebo plus valacyclovir: reconstructed HR 0.62 (95% CI 0.44–0.86)
Landmark survival (reconstructed)
| Time | Aglatimagene plus valacyclovir | Placebo plus valacyclovir |
|---|---|---|
| 6 mo | 100.0% | 100.0% |
| 12 mo | 100.0% | 99.5% |
| 18 mo | 99.5% | 99.1% |
| 24 mo | 99.1% | 97.2% |
| 36 mo | 83.4% | 73.9% |
| 48 mo | 80.6% | 71.8% |
| 60 mo | 79.0% | 70.8% |
Checks against the published figure
- Aglatimagene plus valacyclovir events: printed 82, reconstructed 82 pass
- Aglatimagene plus valacyclovir n: printed 496, reconstructed 496 pass
- Placebo plus valacyclovir events: printed 62, reconstructed 62 pass
- Placebo plus valacyclovir n: printed 249, reconstructed 249 pass
- hazard ratio: printed 0.62, reconstructed 0.616 pass
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Load these data in R or Python
# R
library(survival)
d <- read.csv("https://trialcurve.com/data/trials/aglatimagene-besadenovec-plus-radiotherapy-in-prostate-1.csv")
survfit(Surv(time, event) ~ arm, data = d)
coxph(Surv(time, event) ~ arm, data = d)
# Python
import pandas as pd
from lifelines import KaplanMeierFitter
d = pd.read_csv("https://trialcurve.com/data/trials/aglatimagene-besadenovec-plus-radiotherapy-in-prostate-1.csv")
for arm, g in d.groupby("arm"):
KaplanMeierFitter().fit(g.time, g.event, label=arm).plot_survival_function()
Suggested citation: Lancet Oncol. Author manuscript; Available in PMC 2026 Aug 5. doi:10.1016/S1470-2045(26)00071-9. Reconstructed data: TrialCurve (2026), https://trialcurve.com/trials/aglatimagene-besadenovec-plus-radiotherapy-in-prostate
Report a problem with these data
Related trials
- STAMPEDE (radiotherapy to the primary tumor): Failure-free survival; Overall survival
- TALAPRO-2 (HRR-deficient cohort): Overall survival (interim analysis); PFS2 (investigator-assessed); Radiographic progressio
- AMPLITUDE: Investigator-assessed radiographic progression-free survival; Overall survival; Radiograph
- KEYNOTE-045 (Japanese subgroup): Duration of response; Overall survival; Progression-free survival
- RADICALS-RT (long-term follow-up): Biochemical progression-free survival; Overall survival
- RADICALS-HD (three-way comparison): Freedom from distant metastasis; Metastasis-free survival; Overall survival; Time to salva
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials